3XI Stock Overview
A biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Biomind Labs Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.22 |
| 52 Week High | US$0.72 |
| 52 Week Low | US$0.0005 |
| Beta | 0.028 |
| 1 Month Change | -36.36% |
| 3 Month Change | -49.78% |
| 1 Year Change | 3,633.33% |
| 3 Year Change | -75.65% |
| 5 Year Change | n/a |
| Change since IPO | -81.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3XI | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -22.2% | 2.6% | 1.1% |
| 1Y | 3,633.3% | -7.8% | 10.3% |
Return vs Industry: 3XI exceeded the German Pharmaceuticals industry which returned -7.8% over the past year.
Return vs Market: 3XI exceeded the German Market which returned 10.3% over the past year.
Price Volatility
| 3XI volatility | |
|---|---|
| 3XI Average Weekly Movement | 62.7% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 3XI's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3XI's weekly volatility has decreased from 2640% to 63% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 5 | Alejandro Antalich | www.biomindlabs.com |
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment; BMND06 is in Phase I clinical trial for treatment of morbid obesity; and BMDO9 is in Phase I clinical trial for treatment of Parkinson’s disease. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammatory disorders, and BMND07 for treating major depressive disorder.
Biomind Labs Inc. Fundamentals Summary
| 3XI fundamental statistics | |
|---|---|
| Market cap | €22.79m |
| Earnings (TTM) | -€673.36k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-33.8x
P/E RatioIs 3XI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3XI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$704.80k |
| Earnings | -US$704.80k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0091 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -58.0% |
How did 3XI perform over the long term?
See historical performance and comparison